US Food and Drug Administration (FDA) Approvals of GLP-1 and GLP1 /GIP RAs 11,22-34 However, these labels are being expanded to include additional indications for patients with a spectrum of other cardiometabolic conditions, such as obesity, cardiovascular disease, chronic kidney disease, and obstructive sleep apnea
The central pillar remains energy balance: a moderate, sustainable calorie deficit that does not rely on the total exclusion of foods
Since alcohol is known to increase this stress, particularly in the brain and liver, adequate selenium levels can help buffer the impact and support the bodys natural detoxification processes
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
Providers and insurance companies set the actual bar
For acute gastrointestinal losses, medically formulated oral rehydration salts (ORS) available from pharmacies are more appropriate than sports drinks
